Biologically effective doses in radiotherapy of cervical carcinoma

Neoplasma

Volumn 51, Issue 3, 2004, Pages 228-238

  Urbanski, K ^a   Gasinska, A ^a,c   Pudelek, J ^a   Fowler, J F ^b   Lind, B ^c   Brahme, A ^c  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

BED; Bladder; Cervical cancer; LDR MDR; NTD; Rectum

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL KILLING; CELL PROLIFERATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; RADIATION BEAM; RADIATION DOSE; RADIATION DOSE FRACTIONATION; TUMOR CELL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA;

EID: 3042621474     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. BARENDSEN GW. Dose fractionation, dose rate and isoeffect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982; 8: 1981-1997.
2. COX DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
3. COX JD, STETZ J, PAJAK TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [edtorial]. Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
4. CLARK BG, SOUHAMI L, ROMAN TN, CHAPPELL R, EVANS MDC, FOWLER JF. The prediction of late rectal complications in patients treated with high dose-rate brochytherpay for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1997; 38: 989-993.
5. DALE RG, JONES B. The clinical radiobiology of brachytherapy. Br J Radiol 1998; 71: 465-483.
6. EIFEL PJ. Chemoradiation for carcinoma of the cervix: advances and opportunities. Radiat Res 2000; 154: 229-236.
7. FOWLER JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62: 679-694.
8. FOWLER JF. Rapid repopulation in radiotherapy: A debate on mechanism: The phantom of tumour treatment - continually rapid proliferation unmasked. Radiother Oncol 1991; 22: 156-158.
9. FOWLER JF. Dose reduction factors when increasing dose rate in LDR or MDR brachytherapy of carcinoma of the cervix. Radiother. Oncol 1997; 45: 49-54.
10. FYLES A, KEANE TJ, BARTON M, SIMM J. The effect of treatment duration in local control of cervix cancer. Radiother Oncol 1992; 25: 273-279.
11. GASINSKA A, URBANSKI K, JAKUBOWICZ K, KLIMEK M, BIESAGA B, WILSON GD. Tumour cell kinetics as a prognostic factor in squamous cell carcinoma of the cervix treated with radiotherapy. Radiother Oncol 1999; 50: 77-84.
12. GASINSKA A, FOWLER JF, LIND BL, URBANSKI K. Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone. Acta Oncol. In press.
13. GIRINSKY T, REY A, ROCHE B, HAIE C, GERBAULET A et al. Overall treatment time in advanced cervical carcinoma: A critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993; 27: 1051-1056.
14. JONES LC, METCALFE P, HOBAN P, FOX Ch. Standard effective doses for proliferative tumours. Phys Med Biol 1999; 44: 2127-2142.
15. KAPLAN EL, MEIER P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1956; 53: 457-481.
16. KAROLEWSKI K, KORZENIOWSKI S, SOKOLOWSKI A, URBANSKI K, KOJS Z. Prognostic significance of pretherapeutic and therapeutic factors in patients with advanced cancer of the uterine cervix treated with radical radiotherapy alone. Acta Oncol 1999; 38: 461-468.
17. KEANE T, FYLES A, O'SULLIVAN B, BARTON M, MAKI E, SIMM J. The effect of treatment duration on local control of squamous carcinoma of the tonsil and carcinoma of the cervix. Sem Radiat Oncol 1992; 2: 26-28.
18. LANCIANO RM, PAJAK TF, MARTZ K, HANKS GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A patterns of care study. Int J Radiat Oncol Biol Phys 1993; 25: 391-397.
19. LEBORGNE F, FOWLER JF, LEBORGNE JH, ZUBIZARRETA E, CHAPPELL R. Fractionation in medium dose rate brachytherapy of cancer of the cervix. Int J Radiat Oncol Biol Phys 1996; 35: 907-914.
20. LEBORGNE F, FOWLER JF, LEBORGNE JH, ZUBIZARRETA E, CHAPPELL R. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix. Radiat Oncol Invest 1997; 5: 289-299.
21. LEBESQUE JV, KEUS RB. The simultaneous boost technique: the concept of the normalized total dose. Radiother Oncol 1991; 222: 45-55.
22. LINDELL A. Carcinoma of the uterine cervix: Incidence and influence of age. Acta Radiol 1952; Suppl 92: 33-101.
23. MACIEJEWSKI B, PREUSS-BAYER G, TROTT KR. The influence of the number of fractions and of overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx. Int J Radiat Oncol Biol Phys 1983; 9: 321-328.
24. MENDENHALL WM, THAR TL, BOVA FJ, MARCUS RB, MORGAN LS, MILLON RR. Prognostic and treatment factors affecting pelvic control of stage IB and II A-B carcinoma of the intact uterine cervix treated with radiation therapy alone. Cancer 1984; 53: 2649-2654.
25. ORTON CG. High and low dose-rate brachytherapy for cervical carcinoma. Acta Oncol 1998; 37: 117-125.
26. PETEREIT DG, SARKARIA JN, CHAPPELL R, FOWLER JF, HARTMANN TJ et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995; 32: 1301-1307.
27. PEREZ CA, GRIGSBY PW, CASTRO-VITA H, LOCKETT MA. Carcinoma of the uterine vervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995; 32: 1275-1288.
28. PREMPREE T, TATANAPHAN V, SEWCHAND W, SCOTT R. The influence of patients' age and tumor grade on the prognosis of carcinoma of the cervix. Cancer 1983; 51: 1764-1771.
29. SCALLIET P, GERBAULET A, DUBRAY R. HDR versus LDR gynecological brachytherapy revisited. Radiother Oncol 1993; 28: 118-126.
30. SCHRIMPF H. Bösartigkeit des Kollumakarzinomas in Verschiedenem Lebensalter. Arch Geschwulstforsch 1953; 5: 134-139.
31. SKLADOWSKI K, LAW MMG, MACIEJEWSKI B, STEEL GG. Planned and unplanned gaps in radiotherapy: the importance of gap position and gap duration. Radiother Oncol 1994; 30: 109-920.
32. SPANOS WJ, KING A, KEENEY E, WAGNER R, SLATER JM. Age as a prognostic factor in carcinoma of the cervix. Gynecol Oncol 1989; 35: 66-68.
33. STANHOPE CR, SMITH JP, WHARTON JT, RUTLEDGE FN, FLETCHER GH, GALLAGER HS. Carcinoma of the cervix. The effect of age on survival. Gynecol Oncol 1980; 10: 188-193.
34. STITT JA, FOWLER JF, THOMADEN BR, BUCHLER DA, PALIWAL BP, KINSELLA TJ. High dose rate intracavitary brachytherapy for carcinoma of the cervix: The Madison system: I. Clinical and radiobiological considerations. Int J Radiat Oncol Biol Phys 1992; 24: 335-348.
35. SZYMCZYK W, SIUDA J, MEDVEY W, POLAK B, POLOK B. Dose distribution in pelvic are in patients treated for cervical cancer. Pol Przegl Rad I Med Nucl 1971; XXXV: 475-480.
36. TAN LT, JONES B, GREEN JA, KINGSTON RE, CLARK PI. Treatment of carcinomas of the uterine cervix which remain bulky after external beam radiotherapy: a pilot study using integrated cytotoxic chemotherapy prior to brachytherapy. Br J Radiol 1996; 69: 165-171.
37. WILSON GD. Limitations if the bromodeoxyuridine technique for measurement of tumour proliferation. Medical Radiology. Current Topics in Clinical Radiobiology of Tumours. Berlin: Springer, 1993.
38. WITHERS HR, TAYLOR JMG, MACIEJEWSKI B. The hazard of the accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131-146.
39. YAES RJ, PATEL P, MARUYAMA Y. On using the liner-quadratic model in daily clinical practice. Int J Radiat Oncol Biol Phys 1991; 20: 1353-1362.